EMPIRE CONSULTING GROUP

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Pharmaceuticals

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 18, 2026

Lobbying activity 1

Health Issues

PBM reform. Issues related to health access. 340B reform issues. Issues related to Most-Favored-Nation prescription drug pricing. Tariffs on pharmaceutical products.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.